Citadel Advisors’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Citadel Advisors’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,609	Closed	-$25.7K	–	15684
2023 Q1	$25.7K	Buy	+8,609	New	+$31.8K	﹤0.01%	12867
2022 Q3	–	Sell	-2,112	Closed	-$16K	–	14022
2022 Q2	$16K	Buy	+2,112	New	+$19.2K	﹤0.01%	12483

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's LABP Position: Q2 2023 in Review

Citadel Advisors sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2023, closing a stake of 8,609 shares — an estimated $25.7K sold.

Citadel Advisors first reported a position in LABP in Q2 2022 and held it in 2 quarters. The position peaked at $25.7K in Q1 2023. 8 funds tracked by Wall St. Rank hold LABP as of Q2 2023.

Citadel Advisors reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 8,609 Landos Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $25.7K.
Citadel Advisors first reported a position in Landos Biopharma, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Citadel Advisors's Landos Biopharma, Inc. Common Stock position peaked at $25.7K in Q1 2023.
8 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.